The changes and clinical significance of osteoprotegerin and receptor activator of nuclear factor kappa B ligand in patients with chronic heart failure

VernacularTitle:慢性心力衰竭患者血浆骨保护素、核因子κB受体活化因子配体的变化及意义
Author: Pengkang YANG ; Wenjun LIU ; Juan WU
Publication Type:Journal Article
Keywords: Heart failure; Osteoprotegerin; Systemic inflammatory response syndrome; Receptor activator of nuclear factor-kappa B ligand
From: Chinese Journal of Postgraduates of Medicine 2012;(31):11-13
CountryChina
Language:Chinese
Abstract: Objective To explore the plasma levels and clinical significance of osteoprotegerin(OPG)and receptor activator of nuclear factor kappa B ligand(RANKL)in patients with chronic heart failure(CHF).Methods In 110 patients with CHF and 80 normal controls,the plasma levels of OPG and RANKL were measured by enzyme-linked immunosorbentassay method.Results The plasma level of OPG in patients with CHF[(135.91±41.83)ng/L]was significantly higher than that in normal controls[(90.13±29.09)ng/L](P＜0.05).The plasma level of RANKL in patients with CHF[(90.82±32.14)ng/L]was significantly higher than that in normal controls[(59.78±20.11)ng/L](P＜0.05).The plasma levels of OPG and RANKL increased with the augment of NYHA functional ranking(P＜0.05).The plasma levels of OPG and RANKL had negative relationship with left ventricular ejection fraction(r=-0.33 and-0.36,P＜0.05).Conclusions The plasma levels of OPG and RANKL in patients with CHF are elevated and related with heart function.OPG and RANKL may participate in the occurrence and development of CHF.